Search

Your search keyword '"Michael D. Schultz"' showing total 4 results
Start Over Author "Michael D. Schultz" Topic sars-cov-2
4 results on '"Michael D. Schultz"'

1. A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts

Author

Michael D. Schultz, John J. Suschak, Davide Botta, Aaron Silva-Sanchez, R. Glenn King, Thomas W. Detchemendy, Chetan D. Meshram, Jeremy B. Foote, Fen Zhou, Jennifer L. Tipper, Jianfeng Zhang, Kevin S. Harrod, Sixto M. Leal, Troy D. Randall, M. Scot Roberts, Bertrand Georges, and Frances E. Lund

Subjects
covid-19, sars-cov-2, receptor binding domain, vaccine, adenovirus vector, viral vector, intranasal, mucosal immunity, Immunologic diseases. Allergy, RC581-607, Therapeutics. Pharmacology, RM1-950
Abstract

The coronavirus disease 2019 (COVID-19) pandemic has illustrated the critical need for effective prophylactic vaccination to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intranasal vaccination is an attractive approach for preventing COVID-19 as the nasal mucosa is the site of initial SARS-CoV-2 entry and viral replication prior to aspiration into the lungs. We previously demonstrated that a single intranasal administration of a candidate adenovirus type 5-vectored vaccine encoding the receptor-binding domain of the SARS-CoV-2 spike protein (AdCOVID) induced robust immunity in both the airway mucosa and periphery, and completely protected K18-hACE2 mice from lethal SARS-CoV-2 challenge. Here we show that a single intranasal administration of AdCOVID limits viral replication in the nasal cavity of K18-hACE2 mice. AdCOVID also induces sterilizing immunity in the lungs of mice as reflected by the absence of infectious virus. Finally, AdCOVID prevents SARS-CoV-2 induced pathological damage in the lungs of mice. These data show that AdCOVID not only limits viral replication in the respiratory tract, but it also prevents virus-induced inflammation and immunopathology following SARS-CoV-2 infection.

Published
2022
Full Text
View/download PDF

2. Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge

Author

R. Glenn King, Aaron Silva-Sanchez, Jessica N. Peel, Davide Botta, Alexandria M. Dickson, Amelia K. Pinto, Selene Meza-Perez, S. Rameeza Allie, Michael D. Schultz, Mingyong Liu, John E. Bradley, Shihong Qiu, Guang Yang, Fen Zhou, Esther Zumaquero, Thomas S. Simpler, Betty Mousseau, John T. Killian, Brittany Dean, Qiao Shang, Jennifer L. Tipper, Christopher A. Risley, Kevin S. Harrod, Tsungwei Feng, Young Lee, Bethlehem Shiberu, Vyjayanthi Krishnan, Isabelle Peguillet, Jianfeng Zhang, Todd J. Green, Troy D. Randall, John J. Suschak, Bertrand Georges, James D. Brien, Frances E. Lund, and M. Scot Roberts

Subjects
COVID-19, SARS-CoV-2, receptor binding domain, vaccine, adenovirus vector, viral vector, Medicine
Abstract

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective prophylactic vaccination to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intranasal vaccination is an attractive strategy to prevent COVID-19 as the nasal mucosa represents the first-line barrier to SARS-CoV-2 entry. The current intramuscular vaccines elicit systemic immunity but not necessarily high-level mucosal immunity. Here, we tested a single intranasal dose of our candidate adenovirus type 5-vectored vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (AdCOVID) in inbred, outbred, and transgenic mice. A single intranasal vaccination with AdCOVID elicited a strong and focused immune response against RBD through the induction of mucosal IgA in the respiratory tract, serum neutralizing antibodies, and CD4+ and CD8+ T cells with a Th1-like cytokine expression profile. A single AdCOVID dose resulted in immunity that was sustained for over six months. Moreover, a single intranasal dose completely protected K18-hACE2 mice from lethal SARS-CoV-2 challenge, preventing weight loss and mortality. These data show that AdCOVID promotes concomitant systemic and mucosal immunity and represents a promising vaccine candidate.

Published
2021
Full Text
View/download PDF

3. Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge

Author

John E. Bradley, Jessica N. Peel, Guang Yang, Todd Green, M. Scot Roberts, Kevin S. Harrod, Amelia K. Pinto, Christopher A. Risley, Aaron Silva-Sanchez, James D. Brien, Alexandria M Dickson, Fen Zhou, Young Ho Lee, Selene Meza-Perez, Davide Botta, John J Suschak, Tsungwei Feng, Vyjayanthi Krishnan, Brittany Dean, Jianfeng Zhang, Esther Zumaquero, Shihong Qiu, Thomas S. Simpler, Bethlehem Shiberu, Isabelle Peguillet, Bertrand Georges, Qiao Shang, R Glenn King, Jennifer L. Tipper, John T. Killian, S. Rameeza Allie, Troy D. Randall, Betty Mousseau, Mingyong Liu, Frances E. Lund, and Michael D. Schultz

Subjects
Immunology, Viral vector, Immune system, Immunity, vaccine, Drug Discovery, medicine, Pharmacology (medical), Pharmacology, receptor binding domain, biology, business.industry, SARS-CoV-2, intranasal, viral vector, adenovirus vector, COVID-19, Vaccination, Infectious Diseases, medicine.anatomical_structure, biology.protein, mucosal immunity, Medicine, Nasal administration, Antibody, business, IgA, CD8, Respiratory tract
Abstract

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective prophylactic vaccination to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intranasal vaccination is an attractive strategy to prevent COVID-19 as the nasal mucosa represents the first-line barrier to SARS-CoV-2 entry. The current intramuscular vaccines elicit systemic immunity but not necessarily high-level mucosal immunity. Here, we tested a single intranasal dose of our candidate adenovirus type 5-vectored vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (AdCOVID) in inbred, outbred, and transgenic mice. A single intranasal vaccination with AdCOVID elicited a strong and focused immune response against RBD through the induction of mucosal IgA in the respiratory tract, serum neutralizing antibodies, and CD4+ and CD8+ T cells with a Th1-like cytokine expression profile. A single AdCOVID dose resulted in immunity that was sustained for over six months. Moreover, a single intranasal dose completely protected K18-hACE2 mice from lethal SARS-CoV-2 challenge, preventing weight loss and mortality. These data show that AdCOVID promotes concomitant systemic and mucosal immunity and represents a promising vaccine candidate.

Published
2021

4. Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice

Author

John T. Killian, Rameeza Allie, Guang Yang, Brittany Dean, Jianfeng Zhang, Young H Lee, John E. Bradley, Esther Zumaquero, Christopher A. Risley, Shihong Qiu, Jennifer L. Tipper, Troy D. Randall, Selene Meza-Perez, Kevin S. Harrod, Aaron Silva-Sanchez, Qiao Shang, Vyjayanthi Krishnan, Betty Mousseau, Isabelle Peguillet, Rodney G. King, Fen Zhou, Mingyong Liu, Jessica N. Peel, Bertrand Georges, Frances E. Lund, Todd Green, Michael D. Schultz, Bethlehem Shiberu, Thomas S. Simpler, Ray Feng, Scot Roberts, and Davide Botta

Subjects
viruses, Mucous membrane of nose, medicine.disease_cause, Article, Immune system, vaccine, medicine, Coronavirus, Lung, receptor binding domain, biology, business.industry, SARS-CoV-2, intranasal, viral vector, adenovirus vector, COVID-19, biochemical phenomena, metabolism, and nutrition, Vaccination, medicine.anatomical_structure, Immunology, biology.protein, mucosal immunity, Nasal administration, Antibody, business, CD8, IgA
Abstract

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective prophylactic vaccination to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intranasal vaccination is an attractive strategy to prevent COVID-19 as the nasal mucosa represents the first-line barrier to SARS-CoV-2 entry. The current intramuscular vaccines elicit systemic immunity but not necessarily high-level mucosal immunity. Here, we tested a single intranasal dose of our candidate adenovirus type 5-vectored vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (AdCOVID) in inbred, outbred, and transgenic mice. A single intranasal vaccination with AdCOVID elicited a strong and focused immune response against RBD through the induction of mucosal IgA in the respiratory tract, serum neutralizing antibodies, and CD4+ and CD8+ T cells with a Th1-like cytokine expression profile. A single AdCOVID dose resulted in immunity that was sustained for over six months. Moreover, a single intranasal dose completely protected K18-hACE2 mice from lethal SARS-CoV-2 challenge, preventing weight loss and mortality. These data show that AdCOVID promotes concomitant systemic and mucosal immunity and represents a promising vaccine candidate.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results